Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > I Think

<< Previous

Bullboard Posts

Next >>

Comment by Amazighon Jan 28, 2022 11:38am

172 Views

Post# 34371496

RE:I Think

Red~One wrote: Everytime anyone answers a question with "maybe, perhaps, conceivably, I think, I heard, to the best of my recall (remember that one?) , could be" .... they should have to put a Twoonie in the swear jar...... Then at the end of all this .....the money would go to me.

I heard you're an idiot and to the best of my recall, I can agree with that. Maybe that statement is a bit harsh or perhaps unfriendly, but I think it suits you. It is conceivable that in the near future when CLAS SP starts rising you may change and we don't see you like the idiot you are now. Could be... But what is certain is that CLAS SP will be higher than $1.30 before 26th April. Cheers

<< Previous

Bullboard Posts

Next >>

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity